Detection of Chromosome Abnormalities Using Cytoplasmic Immunoglobulin Staining and FISH in Myeloma

Methods in Molecular Biology

Volumn 730, Issue , 2011, Pages 159-171

  Mercer, Bruce R ^a   Rayeroux, Kathleen C ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b NONE

Author keywords

Cytoplasmic immunoglobulin staining; FGFR3 IGH; Fluorescence in situ hybridization; IGH MAF; Plasma cell myeloma; TP53

Indexed keywords

IMMUNOGLOBULIN;

ARTICLE; CHROMOSOME ABERRATION; CYTOPLASM; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MULTIPLE MYELOMA; PATHOLOGY; STAINING;

CHROMOSOME ABERRATIONS; CYTOPLASM; HUMANS; IMMUNOGLOBULINS; IN SITU HYBRIDIZATION, FLUORESCENCE; MULTIPLE MYELOMA; STAINING AND LABELING;

EID: 79960034270     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-074-4_12     Document Type: Chapter

References (14)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. (Eds.). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008.
2. Lai JL, Zandecki M, Mary JY, et al. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 1995;85:2490–7.
3. Dewald GW, Kyle RA, Hicks GA, Greipp PR. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985;66:380–90.
4. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995;82:41–9.
5. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001; 98:2229–38.
6. Debes-Marun CS, Dewald GW, Bryant S, et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003;17:427–36.
7. Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007;21:529–34.
8. Chen Z, Issa B, Huang S, et al. A practical approach to the detection of prognostically
9. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003;101:4569–75.
10. Stewart AK, Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 2005; 23:6339–44.
11. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007;109: 3489–95.
12. Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 2007;20:571–96.
13. Fonseca R, Van Wier SA, Chng WJ, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 2006;20:2034–40.
14. Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006; 108:1724–32. significant genomic aberrations in multiple myeloma. J Mol Diagn 2005;7:560–5.